AbCellera Biologics Inc.

NASDAQ:ABCL

Biotechnology

Healthcare
$10.47 -0.28%

-$0.02 today

Market cap
$3.42B
Beta
1.20
P/E (TTM)
-11.4
EPS (TTM)
-$0.47
52W Low $2.75High $6.79

Volume 2.48M

Average 6.37M

Income Statement

Follow revenue through to earnings.

Revenue

$75.13M

FY 2025 · Annual

+160.6% YoY

Operating Income

-$217.10M

FY 2025 · Annual

Net Income

-$146.41M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue375.2M485.42M38.03M28.83M75.13M
Cost of Revenue45.52M66.44M0028.82M
Gross Profit329.69M418.99M38.03M28.83M46.31M
Gross Margin87.9%86.3%100.0%100.0%61.6%
Research & Development62.06M107.88M175.66M167.26M186.83M
Selling, General & Admin48.76M66.76M75.18M85.49M76.58M
Operating Expenses125.27M202.48M275.23M343.6M263.41M
Depreciation & Amortization17.25M33.1M30.89M97M28.82M
EBITDA239.15M260.17M(192.16M)(204.15M)(148.77M)
EBITDA Margin63.7%53.6%-505.3%-708.0%-198.0%
Operating Income204.41M216.51M(237.21M)(314.77M)(217.1M)
Operating Margin54.5%44.6%-623.8%-1091.7%-289.0%
Interest Income3.33M16.08M42.25M38.47M28.33M
Interest Expense5.23M4.05M000
Other Income / Expenses14.74M22.59M63.18M114.37M39.51M
Income Before Tax219.15M239.1M(174.03M)(200.4M)(177.6M)
Pre-Tax Margin58.4%49.3%-457.7%-695.0%-236.4%
Income Tax Expense65.69M80.58M(27.63M)(37.54M)(31.18M)
Net Income153.46M158.52M(146.4M)(162.86M)(146.41M)
Net Margin40.9%32.7%-385.0%-564.8%-194.9%
EPS (Basic)0.560.56(0.51)(0.55)(0.49)
EPS (Diluted)0.480.50(0.51)(0.55)(0.49)
Weighted Avg Shares275.76M285.06M289.17M294.33M298.71M
Weighted Avg Shares (Diluted)318.29M314.83M289.17M294.33M298.71M

ABCL Earnings Waterfall · TTM

NASDAQ:ABCL · Revenue to Net Income

Key Ratios

EPS$-0.48
Gross Margin-80.7%
Net Margin-572.7%
P/E Ratio-18.4
P/S Ratio294.6

Analysis

$67.9M of revenue converted into -$148.3M of net income for the selected period. Gross margin is -80.7% and net margin is -572.7%, showing how much revenue survives after costs and taxes. EPS is $-0.48, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 13, 2026
SC 13G/ASC 13G/A filingNov 13, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
8-KCurrent reportNov 9, 2026

How much revenue does ABCL generate?

AbCellera Biologics Inc. (ABCL) reported $75.13M of revenue in fiscal 2025.

Is ABCL profitable?

AbCellera Biologics Inc. (ABCL) reported -$146.41M of net income, with a net margin of -194.9%.